EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Can FDG-PET assess the response to chemotherapy and predict tissue necrosis in osteosarcoma and Ewing sarcoma?

Lorenzo Andreani iD, Edoardo Ipponi iD, Alfio Damiano Ruinato iD, Tommaso Lupi, Federico Di Sacco iD, Duccio Volterrani iD, Luca Coccoli, Rodolfo Capanna iD

Folia Medica · 2024

DOI: 10.3897/folmed.66.e117148 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Folia Medica, 2024. Verfasst von Lorenzo Andreani und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Sarcoma, Ewing, Fluorodeoxyglucose F18, Osteosarcoma, Bone Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Osteosarcoma (OS) and Ewing sarcoma (ES) represent the pediatric population’s most common malignant bone tumors. 18-Fluorodeoxyglucose positron emission tomography has been shown to be effective in both the diagnostic and staging phases of cancer treatment. In recent years, some studies have also explored the possibility that FDG-PET could have a prognostic role.

Aim

Our research aimed to evaluate if maximum standardized uptake value (SUVmax) variations after chemotherapy could be correlated with tissue necrosis and be linked with patients’ survival rates. Materials and methods : This observational retrospective study included all cases treated for skeletal OS or ES in our institution between 2006 and 2018. We recorded patients’ SUVmax values before and after chemotherapy, the necrosis grade (for those who received surgery), and survivorship. Forty-one cases (17 OS and 24 ES) were included. Among the 36 cases that received surgery, 15 were responders, and 20 were non-responders.

Results

Our data suggested a statistically significant correlation between tumor necrosis and differential SUVmax after neoadjuvant treatment ( p =0.007). In particular, cases with differential SUVmax higher than 4.7 or a variation higher than 63% had better oncological outcomes.

Conclusion

Our study testifies to the effectiveness of FDG-PET in predicting tissue necrosis on ES and OS, thereby representing a promising prognostic factor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sarcoma, EwingFluorodeoxyglucose F18OsteosarcomaBone NeoplasmsPositron-Emission TomographyRadiopharmaceuticalsHumansNecrosisPrognosis

Stichwörter der Autor:innen

Ewing sarcoma necrosis osteosarcoma PET prognosis

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • University of Pisa, Pisa, Italy.

ORCID-Profile: Lorenzo Andreani, Edoardo Ipponi, Alfio Damiano Ruinato, Federico Di Sacco, Duccio Volterrani, Rodolfo Capanna

Zitieren

APA

Andreani, L., Ipponi, E., Ruinato, A. D., Lupi, T., Di Sacco, F., Volterrani, D., Coccoli, L., & Capanna, R. (2024). Can FDG-PET assess the response to chemotherapy and predict tissue necrosis in osteosarcoma and Ewing sarcoma?. Folia Medica. https://doi.org/10.3897/folmed.66.e117148

Vancouver

Andreani L, Ipponi E, Ruinato AD, Lupi T, Di Sacco F, Volterrani D, et al. Can FDG-PET assess the response to chemotherapy and predict tissue necrosis in osteosarcoma and Ewing sarcoma?. Folia Medica. 2024. doi:10.3897/folmed.66.e117148

BibTeX
@article{Andreani2024,
  author = {Andreani, Lorenzo and Ipponi, Edoardo and Ruinato, Alfio Damiano and Lupi, Tommaso and Di Sacco, Federico and Volterrani, Duccio and Coccoli, Luca and Capanna, Rodolfo},
  title = {Can FDG-PET assess the response to chemotherapy and predict tissue necrosis in osteosarcoma and Ewing sarcoma?},
  journal = {Folia Medica},
  year = {2024},
  doi = {10.3897/folmed.66.e117148}
}
Kostenlos starten →